Cinacalcet HCl

Phase 3Small molecule

Amgen

Cinacalcet HCl is one of 37 small molecule programs targeting Hypercalcemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypercalcemiaActive, not recruiting

Secondary HyperparathyroidismActive, not recruiting

Primary HyperparathyroidismActive, not recruiting

HypercalcemiaPhase 1/Phase 2

Active, not recruiting

Secondary HyperparathyroidismPhase 3

Active, not recruiting

Primary HyperparathyroidismPhase 3

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Secondary Hyperparathyroidism

#DrugCompanyPhaseTrials

Zemplar

AbbVie

Approved

12 2

Sensipar

Amgen

Approved

11 3

Rocaltrol

Alnylam Pharmaceuticals

Approved

3 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Approved

3 5

Rayaldee

OOrganon and Co

Approved

2 6

Parsabiv

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

13 7

Hectorol

Sanofi

Phase 3

2 8

Zemplar

Sanofi

Approved

1 9

AMG 333

Amgen

Phase 3

3 10

Hectorol

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Secondary Hyperparathyroidism3 trials

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Terminated· Amgen logo

Amgen·Phase 3·NCT02138838·55 enrolled

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Completed· Amgen logo

Amgen·Phase 3·NCT00094484·400 enrolled

Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)

Unknown status·EENRICO VERRINA·Phase 2/3·NCT01479088·30 enrolled

Primary Hyperparathyroidism1 trial

An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 3·NCT01460030

Efficacy and Safety1 trial

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

Completed·KKyowa Kirin China Pharmaceutical Co., Ltd.·Phase 4·NCT03123406·750 enrolled

Hypercalcemia1 trial

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Terminated·MMontefiore Medical Center·Phase 1/2·NCT00415584·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cinacalcet HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cinacalcet HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cinacalcet HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

Cinacalcet HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Secondary Hyperparathyroidism3 trials

Primary Hyperparathyroidism1 trial

Efficacy and Safety1 trial

Hypercalcemia1 trial

References

Drug Info

Quick Facts

Related News